Albemarle — Feb 12, 2025 release

Ketjen outlook assumes favorable product revenue mix, lower input costs and the continuation of its turnaround plan execution. Segment FY 2025E Specialties net sales $1.3 - $1.5 billion Specialties adjusted EBITDA $210 - $280 million Ketjen net sales $1.0 - $1.1 billion Ketjen adjusted EBITDA $120 - $150 million 3 Other Corporate Outlook Considerations Albemarle expects its 2025 capital expenditures to be in the range of $700 million to $800 million, down more than 50% from $1.7 billion in 2024. This level of spending reflects a prioritization on sustaining existing assets and resources, with the remainder allocated to select growth projects and high-return, quick payback improvements. Other Corporate FY 2025E Capital expenditures $700 - $800 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40%) - 25% Corporate costs $70 - $100 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a)    Adjusted effective tax rate dependent on lithium market prices and geographic income mix Cash Flow and Capital Deployment Cash from operations of $702 million for the year ended December 31, 2024 decreased $623 million compared to the prior-y ear period. This was driven by lower adjusted EBITDA and reduced dividends received from equity investments, partially offset by inflows from working capital. Capital expenditures of $1.7 billion were in-line with outlook considerations and decreased by $4